The Gut Microbiome and Schizophrenia: The Current State of the Field and Clinical Applications

Tomasz Szeligowski¹, Alexandra Lim Yun², Belinda R. Lennox² and Philip W. J. Burnet²*

¹ St. Edmund Hall College, University of Oxford, Oxford, United Kingdom, ² Department of Psychiatry, University of Oxford, Oxford, United Kingdom

Schizophrenia is a debilitating psychiatric disorder, leading to both physical and social morbidity. Despite its importance, the etiology of schizophrenia remains poorly understood. Furthermore, its mainstream treatments fail to address all aspects of the disorder and are associated with significant side-effects. Recently, there has been growing interest in the relationship between the gut microbiome and mental health, including in schizophrenia. In this article, we review the existing evidence implicating dysbiosis in schizophrenia and discuss how the presumed dysbiosis could fit within known hypotheses of its pathogenesis, focusing on inflammation, tryptophan metabolites, and BDNF levels. We also evaluate the clinical potential of manipulating the gut microbiome with probiotics and prebiotics as adjunctive treatments in schizophrenia, based on existing clinical and pre-clinical studies. Overall, the current data showing microbiome alterations in schizophrenia are highly discrepant and insufficient to conclude whether microbiome changes are associated with increased risk of the disorder, or are simply the result of external factors or treatment. Despite some encouraging results of pro/prebiotic supplementation, there is also inconclusive evidence for their efficacy in schizophrenia. Thus, further research and more clinical trials are needed to test the validity of manipulating the gut microbiome to improve the treatment of this disorder.

Keywords: inflammation, microbial communities, psychosis, antipsychotics, supplementation

INTRODUCTION

Schizophrenia is a debilitating psychiatric disorder, characterized by positive symptoms (delusions, hallucinations, aberrant flow of thoughts), and negative symptoms (apathy, withdrawal, slowness) (1). It affects ~21 million people worldwide, and causes significant physical and social morbidity (2, 3). Its heritability is estimated at ~80% based on concordance rates in monozygotic twins (4), while risk profile scores constructed from alleles associated with schizophrenia explain ~7% of variation in the liability to schizophrenia (5). Thus, genetics cannot fully explain its etiology, and so other factors, particularly the environment, need to be explored (6, 7). Furthermore, the current treatments for schizophrenia do not address all aspects of this disorder (8) and are associated with considerable side-effects (9), necessitating development of improved treatment strategies.

The gut microbiome has been implicated in psychiatric disorders, and is well-described for depression, with dysbiosis suggested in clinical studies (10) and fecal transplants from depressed patients to germ-free rats shown to induce depressive-like behaviors (11). The gut microbiome is a rich community of microbes which are diverse and personalized, though dominated by...
phyla Bacteroidetes and Firmicutes (12). It is also dynamic, influenced by lifestyle factors such as diet (13), sleep (14), or stress (15). The personal and dynamic nature of the gut microbiome is why dysbiosis remains a poorly defined concept, despite the common use of this term in the literature. Accurate definition of a healthy baseline microbiome is near impossible to establish, so it is unclear what qualitative and quantitative changes in the microbiome composition constitute functionally significant deviations from the “norm,” what thresholds should be set when assessing the importance of relative deviations from controls, and whether these should be different for various populations. 

Bearing these limitations in mind, we take the term dysbiosis to mean microbiome profiles which are significantly different from controls and which could have functional significance in pathological processes if conclusively proven. Research into the role of the microbiome in schizophrenia is still in its infancy. In this article, the evidence implicating dysbiosis in schizophrenia, and how it could fit within existing hypotheses of schizophrenia pathogenesis will be appraised. Furthermore, the therapeutic potential of pre/probiotics in schizophrenia will be discussed.

**EVIDENCE FOR DYSBIOSIS IN SCHIZOPHRENIA**

To date, six studies have been published investigating microbiome differences between healthy controls and individuals with schizophrenia (Table 1). Unaltered microbial richness/diversity was predominantly reported, but with significant differences in the abundance of specific taxa between groups. Interestingly, one study reported that among patients who clustered with controls at baseline, 70% experienced remission within 12 months, compared to only 28% with “abnormal” microbiota—an association which was not weakened by including baseline GAF score as a covariate (21). There is, however, considerable discord between these results. At phylum level, Proteobacteria and Firmicutes were found both significantly elevated and reduced in schizophrenia. This is also the case for taxa within the class Clostridia, despite one study identifying this class as a whole to be enriched in schizophrenia (19). Importantly, one of these studies investigated the oropharyngeal microbiome which is structurally distinct from the gut microbiome (20). Perhaps the only truly consistent finding is a significant elevation of Lactobacilli in schizophrenia and people at increased risk of schizophrenia, which even correlated with symptom severity (21). This is perplexing, considering that Lactobacilli are common components of probiotics, thought to confer benefits for mental health.

Several factors could explain these inconsistencies. Firstly, all studies used small sample sizes (<100 patients), which could explain why certain differences did not reach statistical significance, and why differences are reported at selected taxonomic levels, thus hindering comparisons between studies. Reporting differences at selected taxonomic levels has an additional pitfall—members of the same taxon may differ significantly in terms of their physiological role and impact on pathological processes. This is obviously true for higher taxonomic levels which include increasingly dissimilar groups of bacteria, but is likely also true at genus or even species level. Such variation could explain why Lactobacilli can be implicated in both the pathogenesis of psychiatric disorders and confer benefits in them, depending on which specific subtype of is present. Secondly, the studies differed in exclusion of potential confounders, such as smoking, or co-morbid metabolic and cardiovascular illnesses, all of which affect the microbiome. Patient groups also differed in age, stage of illness, and treatment status. Indeed, antipsychotics have significant anti-commensal activity (22), and in rodents, olanzapine has been shown to elevate Firmicutes and decrease Bacteroidetes (23, 24), which was paralleled in human antipsychotic trials (25, 26), although not universally (27). These results bear resemblance to some of those reported in Table 1, and suggest that the microbiome was affected by treatment status. However, one implication of this is that if antipsychotic treatment impairs the microbiome, then auxiliary interventions aimed at restoring microbiome function could prove beneficial. Thirdly, the methods used in these papers are not consistent, which might alter the obtained taxonomic profiles and further hinder comparisons. While most studies utilized 16S rRNA gene sequencing as the taxonomic marker, different regions of the gene were used (V3 and V4) along with different primers, which is known to affect the outcomes of 16S rRNA gene-based diversity studies due to variation in the evolutionary rates of different regions of this gene (28). Additionally, one study used shotgun metagenomic sequencing on throat swab samples (20). Aside from the problem of differences between oropharyngeal and intestinal microbiomes, an important caveat of this approach is that the abundance of host DNA in swab samples may impair the accuracy of microbiome profiling (29).

Considering the intrinsic variations in microbiome profiles, methodological consistency is necessary to generate data which will allow useful and accurate comparisons across studies.

The existing studies implicating dysbiosis in schizophrenia are all cross-sectional, hence causal relations cannot be inferred. Thus, large-scale prospective studies are needed, to identify whether certain microbiome profiles are associated with increased risk of developing schizophrenia. Fecal microbiome transplants have also been used to demonstrate causal roles of microbiome in disease, but will be challenging to implement in schizophrenia due to the lack of accurate animal behavioral correlates. In one study, fecal transplantation from schizophrenia patients to GF mice led to hyperactivity, reduced immobility in the forced swimming test (behavioral despair), and exaggerated startle response (18). Although these behaviors are seen in schizophrenia, they are not unique to it, and certain tests such as the Y-maze, sociability test, and pre-pulse inhibition test did not reveal differences, suggesting either that the microbiome does not affect all aspects of schizophrenia, or that the findings were...
TABLE 1 | Summary of studies implicating dysbiosis in schizophrenia.

| Study design | (Microbial richness/diversity) | Significantly more abundant taxa in schizophrenia | Significantly more abundant taxa in controls |
|--------------|--------------------------------|--------------------------------------------------|---------------------------------------------|
| 1^ Study group: 81 high-risk subjects (at least one first-degree relative with schizophrenia), 19 ultra-high risk subjects (defined by structured interview for prodromal syndromes), 69 healthy controls; all participants were 13–30 year-old Han Chinese individuals  
Exclusion criteria: GI and endocrine diseases, serious organ disorders, history of psychiatric disorders and corresponding treatment, use of medication within previous 3 months  
Experimental method: 16S rRNA gene sequencing from fecal samples |
| 1^ Study group: 64 schizophrenic patients, and 53 healthy controls; 18–65 year-old Han Chinese individuals  
Exclusion criteria: chronic disease in the last 3 months, use of medication within the last 6 months (including antibiotics and probiotics, but excluding antipsychotic medication)  
Experimental method: 16S rRNA gene sequencing from fecal samples |
| 1^ Study group: 63 schizophrenic patients, 69 healthy controls; most patients receiving antipsychotic medication; participants recruited from the First Affiliated Hospital of Chongqing Medical University  
Exclusion criteria: other physical and mental disorders; use of antibiotics, probiotics, and prebiotics within 1 months before sample collection  
Experimental method: 16S rRNA gene sequencing from fecal samples |
| 1^ Study group: 25 outpatients with schizophrenia or schizoaffective disorder, 25 healthy controls; aged between 30–76; most schizophrenic patients were receiving antipsychotic medication  
Exclusion criteria: Other major psychiatric disorders, substance abuse, major neurological disorders  
Experimental method: 16S rRNA gene sequencing from fecal samples |

(Continued)
not actually indicative of a schizophrenia-like phenotype. Finally, there is very little data on possible sources of dysbiosis, with C-section—a commonly suggested cause of dysbiosis (30)—found not to be associated with schizophrenia (31, 32).

### POTENTIAL DIAGNOSTIC APPLICATION

Two key studies have explored whether microbiome differences could serve as biomarkers for schizophrenia. One investigation demonstrated that the disorder is associated with changes in *Gammaproteobacteria* at class level, *Enterobacteriaceae* at order level, and *Bacteroides fragilis* at species level (17), whereas another determined that a panel consisting of *Aerococcaceae, Bifidobacteriaceae, Brucellaceae, Pasteurellaceae*, and *Rikenellaceae* is sufficient to distinguish patients from controls (18). However, much like with data in Table 1, there is discord in the bacterial taxa identified as markers in these studies, which could again reflect small sample sizes and insufficient overlap between studied populations. Furthermore, investigations of the gut microbiome in depression identified similarly discordant patterns of alterations, and showed a degree of overlap to changes seen in schizophrenia (33). This lack of specificity limits the potential diagnostic usefulness of the data and indeed, its robustness in demonstrating dysbiosis that is characteristic to schizophrenia.

### HOW COULD DYSBIOSIS CONTRIBUTE TO SCHIZOPHRENIA?

Inflammatory responses have long been implicated in schizophrenia [reviewed in (34)], although their origins are not understood. Schizophrenia is associated with elevated levels of IL-6, IL-8, and TNF-α, and reductions in the anti-inflammatory IL-10 (35). Moreover, elevated antibodies to *Saccharomyces cerevisiae* (markers of intestinal inflammation) have been identified (36), which is consistent with GI pathologies being among the most common co-morbidities of schizophrenia (37). Dysbiosis could exacerbate inflammation in the disorder through increased intestinal permeability. Indeed, elevated levels of the bacterial translocation marker sCD14 have been observed in schizophrenia (38), and in another study *Roseburia, Coprococcus*, and *Blautia* were reduced (17). These species mediate butyrate production (39), which has been shown to enhance the intestinal barrier function by facilitating tight junction assembly in monolayers intestinal cell-lines (40). In addition, genes involved in immunity are among the most commonly appearing in GWAS analyses of schizophrenia (5), suggesting that perhaps a genetic component driving inflammation is more significant. It is also possible that dysbiosis facilitates bacterial infections and contributes to inflammation—a hypothesis consistent with a study indicating bacterial infections as risk factors for schizophrenia (41). Additionally, the gut microbiome has been reported to regulate blood-brain barrier permeability (42), and so dysbiosis could potentially facilitate CNS infection and inflammation, which are also associated with schizophrenia (43).
There also exists a link between the immune system and the conversion of tryptophan to kynurenate (44). Kynurenate is a broad-spectrum glutamate receptor antagonist, and N-Methyl-D-Aspartate Receptor (NMDAR) hypofunction is implicated in schizophrenia [reviewed in (45)]. Elevated kynurenate levels have been observed in post-mortem schizophrenia brain tissue (46), while rats treated with kynurenine-3-monooxygenase inhibitors have reduced pre-pulse inhibition (reflecting the inability of schizophrenia patients to filter out extraneous stimuli), along with increased firing rate and burst firing activity of VTA dopaminergic neurons, indicating the dopamine hyperactivity associated with schizophrenia (47). Indoleamine-2,3-dioxygenase (IDO) is responsible for the rate-limiting step in conversion of tryptophan down the kynurenine pathway. Its key function is depleting tryptophan during immune responses to prevent pathogenic growth and dampen immune responses (44). Hence, IDO is upregulated by cytokines such as IFN-γ and TNF-α (44), and in schizophrenia, increased TNF-α has been observed.

The gut microbiome might affect the balance of tryptophan metabolism directly. A study comparing germ-free to control mice identified that GF mice had significantly higher tryptophan availability and decreased kynurenine:tryptophan ratio, which was increased upon colonization (48). In another study, administration of *Bifidobacterium infantis* to rats elevated plasma kynurenate (49). However, a decrease in the kynurenine:tryptophan ratio was observed, indicating reduced overall tryptophan metabolism down the kynurenine pathway. Importantly, there are no studies directly linking specific microbiome profiles in schizophrenia to kynurenate alterations. It is also important to mention that quinolinic acid is an NMDAR agonist, so it is difficult to extrapolate alterations of the kynurenine pathway directly to NMDAR dysfunction.

**THE MICROBIOME AND BRAIN-DERIVED-NEUROTROPHIC FACTOR (BDNF)**

BDNF is a key neurotrophin involved in neurodevelopment, particularly in learning and memory processes, and neurodevelopmental models of schizophrenia often include BDNF alterations, focusing on its role in the cognitive dysfunction in the illness [reviewed in (50)]. Reduced BDNF levels have been observed both in post-mortem hippocampal samples (51), and in the plasma of drug-naïve patients with schizophrenia (52, 53), while low baseline BDNF levels are associated with worse response to antipsychotic treatment (54).

In rodent studies, broad-spectrum antimicrobials have been found to significantly lower BDNF and TrkB expression in mouse hippocampus (55), though another study with similar design found significantly increased BDNF levels in the hippocampus, paralleled by increased abundance of *Lactobacilli* and *Actinobacteria*, and decreased abundance of γ-Proteobacteria and *Bacteroidetes* (56). These conflicting results are problematic, and it remains unclear whether the BDNF changes were mediated by the microbiome and/or the antibiotics themselves. GF mice were found to have lower BDNF expression in the hippocampus in two separate studies (57, 58), however colonization of GF NIH Swiss mice with BALB/c microbiota was found to reduce BDNF expression at 1 week post-transfer compared to NIH Swiss microbiota, but not at 3 weeks (56). Again, none of these studies is directly related to the microbiome in schizophrenia, and more convincing data could be obtained from studies analyzing the effects of FMT from schizophrenia patients on BDNF expression. Interestingly, inflammatory responses have also been associated with decreased hippocampal BDNF expression, providing an additional potential link between BDNF levels and altered gut microbiome (59).

**PREBIOTICS IN SCHIZOPHRENIA**

Prebiotics are substrates utilized by host microorganisms, providing favorable conditions for “beneficial” bacteria (60). They commonly include non-digestible fructan oligosaccharides (FOS) and galactan oligosaccharides (GOS), selectively degraded by *Bifidobacteria*. Recently, a study has shown the potential of using prebiotics as an adjunctive treatment in schizophrenia, and was based on animal studies that explored two aspects of schizophrenia: cognitive dysfunction and antipsychotic-mediated weight gain.

There is strong evidence that schizophrenia and its treatment are associated with impaired cognitive functions. Schizophrenia subjects perform 1.5–2.0 standard deviations below healthy controls in a number of neurocognitive tasks, with largest impairments observed in working memory, attention, problem solving, processing speed, and social cognition (61). Particularly alarming are studies showing that antipsychotic drugs can induce cognitive impairments—risperidone was found to decrease spatial working memory despite clinical improvement (62), while lowering the dose of risperidone or olanzapine was found to significantly improve RBANS and D-KEFS scores (63). These changes can have significant functional implications such as poor work performance, hence addressing them is important in effective treatment.

Ingestion of the B-GOS® prebiotic formulation was found to significantly improve cognitive flexibility in rats (64). Although reduced cognitive flexibility is not unique to schizophrenia, B-GOS® supplementation in this disorder improved global cognitive performance measured by the Brief Assessment of Cognition in Schizophrenia [BACS, (61)], compared to placebo (65). This clearly requires replication with a larger study which should also include assessments of positive and negative symptoms so that the full therapeutic potential of prebiotics in schizophrenia is understood.

Although the mechanisms underlying the pro-cognitive effect of B-GOS® in schizophrenia are not clear, prebiotic supplementation in rats was also found to increase responses of PFC pyramidal neurones to the application of NMDA, and elevate cortical expression of GluN2B and GluN2A NMDA receptor subunits (64, 66). Furthermore, elevated hippocampal levels of BDNF have been reported (66). These changes are highly pertinent to schizophrenia, as NDMA hypofunction...
and decreased BDNF levels are thought to be involved in its pathogenesis, and its associated cognitive impairment (67).

THE PROBLEM OF OBESITY IN SCHIZOPHRENIA, AND THE POTENTIAL BENEFITS OF PREBIOTICS

Antipsychotic treatment is associated with increased body weight, and it is thought to be a key reason for higher rates of obesity among people with schizophrenia, along with lifestyle and social factors (68). This was robustly demonstrated in a meta-analysis of studies investigating this phenomenon, with clozapine and olanzapine increasing weight by >4 kg after 10 weeks of treatment (69). Furthermore, second-generation antipsychotics were found to induce extreme weight gain (≥7% body weight gain) in 7.7–17% of patients within the first year of treatment (70).

The relationship between obesity and schizophrenia is complicated and deserves further attention when discussing the role of the microbiome in this disorder. Obesity is known to be associated with altered gut microbiota, with most convincing evidence showing that transfer of "obese" microbiota to GF mice is associated with weight gain (71). However, the precise nature of those alterations is unclear, much like those in schizophrenia. Some studies identified a decrease in the abundance of Bacteroidetes and increase in Firmicutes [reviewed in (72)], which is interestingly a pattern also reported following olanzapine treatment (as discussed above)—a drug known to induce weight-gain. However, as there is such inconsistency among studies on the microbiomes in both conditions, it is impossible to make useful comparisons between them. Interestingly, there is evidence that the pathways discussed above as potentially affected by the microbiome in schizophrenia might also be affected in obesity. This pertains primarily to the inflammatory hypotheses of schizophrenia, as obesity is known to induce a chronic low-grade inflammatory state, with elevated levels of cytokines including IL-6 and TNF-α [reviewed extensively in (73)]. The parallels extend, however, further. Mutations in the BDNF gene have been found to be associated with hyperphagia and obesity in people (74, 75), while exogenous BDNF administration was shown to induce weight loss in animal models (76), although studies on serum BDNF levels in obese individuals have yielded ambiguous results (77). Likewise, metabolomic studies have shown elevated levels of kynurenate associated with high BMI in both adults (78) and children (79).

Unfortunately, interpreting the complicated relationship between schizophrenia, obesity, and the microbiome is made almost impossible by the lack of data indicating causal relationships. Perhaps surprisingly, two studies found a negative

FIGURE 1 | Pathways potentially affected by the microbiome in schizophrenia.
correlation between body weight and symptom severity in schizophrenia (80, 81), but this was likely an artifact of the effects of atypical antipsychotics on both weight and symptoms. On its own, however, obesity was found to be associated with lower cognitive function, although it is unclear which is antecedent, and whether obesity triggers specific mechanisms affecting cognition (82). Thus, it is unknown whether obesity could have a direct impact on symptoms of schizophrenia, or whether it is merely a side-effect of treatment or an associated morbidity with shared pathophysiological aspects, like BDNF alterations and inflammation. Likewise, there is no clear indication whether the changes in BDNF and kynurenic levels are a contributing cause or a consequence of obesity, whether they are of clinical significance, and whether the microbiome has any impact on them. Nonetheless, considering the importance of obesity in schizophrenia, it would be useful to see detailed studies analyzing the impact of obesity on specific pathophysiological correlates of this disorder, as well as methodologically consistent studies comparing microbiome profiles between schizophrenia and obesity, searching for common signatures.

Regardless of the impact of obesity on the pathophysiology of schizophrenia, the problem of obesity in the disorder needs to be addressed due to its medical implications, and prebiotics could prove useful for this purpose. The administration of B-GOS® reduced olanzapine-induced weight gain in rats (65), whereas in a mouse model of metabolic syndrome, an oligofructose prebiotic caused a trend decrease in weight gain, reductions in food and liquid intake and improved glucose tolerance (83). Prebiotic metabolism by gut bacteria produces short-chain fatty acids (SCFAs), which are agonists of G-protein coupled receptors GPR41 and GPR43 (84). These receptors are expressed in adipocytes, inhibit lipolysis and reduce plasma levels of free fatty acids (85). This could provide a potential mechanism for prebiotic-induced weight normalization and protection against metabolic syndrome, and is also consistent with reduced SCFA-producing bacteria reported in one study in subjects with schizophrenia (17). However, the metabolic effects of the B-GOS® prebiotic in rats were not observed in schizophrenia subjects following a 12 week supplementation (65). In this instance it is noteworthy that in rats the B-GOS® was administered 7 days prior to antipsychotic, whereas the schizophrenia patients had been on medications for several months or years prior to B-GOS® intake. Perhaps prebiotic supplementation would have more beneficial effects of started in parallel with antipsychotic prescription.

**PROBIOTICS IN SCHIZOPHRENIA**

Probiotics contain living beneficial bacteria, typically from genera *Lactobacilli* and *Bifidobacteria* (86). A randomized, placebo-controlled trial of a combination of *Lactobacillus rhamnosus* and *Bifidobacterium lactis* Bb12 in schizophrenia did not change PANSS scores over the course of the 14 week trial (87), though a trend increase in plasma BDNF was observed (88). This effect was also reported in a separate trial of *Bifidobacterium breve* in rats (89). The treated patients also reported less severe bowel movement difficulties, an important observation considering that constipation is a common side-effect of antipsychotic treatment (90) and can be fatal (91).

Recently, a probiotic supplement containing *Lactobacilli* and *Bifidobacterium bifidum* was given with vitamin D to schizophrenia subjects, which resulted in a significant improvement in the general and total PANSS scores, decreased circulating CRP levels and enhanced total antioxidant capacity of plasma, indicating symptomatic improvement and reduced inflammation (92). However, it is uncertain which component of the intervention was responsible for those changes. In another study of schizophrenia, consumption of *Bifidobacterium breve* A-1 for 4 weeks improved PANSS and anxiety/depression scores, increased levels of IFN-γ, IL-1R1, IL-10, IL-22, and decreased levels of TNF-α (93). The psychological effects are significant as the prevalence of depression and panic disorder in schizophrenia patients is 50 and 15% respectively (93). The increase in IL-22 is perplexing, as IL-22 is associated with both inflammatory reactions, and maintenance of the intestinal barrier and host responses against intestinal bacterial pathogens (94). The increased expression of IL-10 and decreased expression of TNF-α may further suggest anti-inflammatory effects, but is countered by elevated pro-inflammatory TNF-β and IL-1R1 (95, 96).

Taken together, the results of probiotic trials are highly discrepant, which could reflect differences in the treatments used. There is, however, preliminary evidence that probiotic supplementation could benefit people with schizophrenia both in terms of symptoms and co-morbid conditions, despite the apparent lack of effect on core aspects of the disorder. What is truly needed are larger-scale studies with consistency in treatment choices and measured outcomes.

**CONCLUSION**

The existing evidence for dysbiosis as a factor in the pathogenesis of schizophrenia is underwhelming. None of the available studies are prospective, making causal relationships unfeasible, and the data is plagued with methodological inconsistencies. However, if future studies confirm that dysbiosis predicts schizophrenia, then it could link a number of observations in schizophrenia patients, such as raised inflammatory markers or altered BDNF and kynurenic levels, and thus contribute to the increasingly complex picture of its etiology (Figure 1). Despite limited evidence, there is promise in the use of pre/probiotics as auxiliary treatments in schizophrenia, aimed at improving side-effects of antipsychotics and complementing their action, particularly in terms of cognitive impairments. Overall, we should look with anticipation toward new studies published in this field.

**AUTHOR CONTRIBUTIONS**

TS and PB made an equal contribution to the conceptualization and drafting of the manuscript. TS drafted the final version of the document and constructed the accompanying figure and table. BL provided a significant contribution to clinical content and proofreading. AL and PB made equal contributions to scientific content proofreading.
54. Lee BH, Kim YK. Increased plasma brain-derived neurotropic factor, N-methyl-D-aspartate receptor subunits and D-serine. Neurochem. Int. (2013) 63:756–64. doi: 10.1016/j.neuint.2013.10.006

57. Kao AC-C, Safariokova J, Marquardt T, Mullins B, Lennox RR, Burnet PWJ. Pro-cognitive effect of a prebiotic in psychosis: a double blind placebo controlled cross-over study. Schizophr. Res. (2019) 208:460–61. doi: 10.1016/j.schres.2019.03.003

59. Calabrese F, Rossetti AC, Racagni G, Gass P, Riva MA, Molloen R. Brain-derived neurotrophic factor: a bridge between inflammation and neuroplasticity. Front Cell Neurosci. (2014) 8:430. doi: 10.3389/fncel.2014.00430

68. Manu P, Dima L, Shulman M, Vancampfort D, De Hert M, Correll CU. Antipsychotic-induced weight gain: a comprehensive research synthesis. Acta Psychiatr. Scand. (2009) 120:393–408. doi: 10.1111/j.1600-0447.2009.01446.x

69. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry. (1999) 156:1616–26. doi: 10.1176/ajp.156.11.1616

70. Bistolfi M, Caputi V, Baranzini N, Dalman C, Lewis G, Jones PB. Childhood infection and adult schizophrenia: a meta-analysis of population-based studies. Schizophr. Res. (2012) 139:161–8. doi: 10.1016/j.schres.2012.05.023

72. Bruni V, Al-Ashmakh M, Kowal C, Anuar F, Abbaspour A, Toth M, et al. The microbiome-gut-brain axis during early life regulates the hippocampal serotonergic system in a sex-dependent manner. Mol. Psychiatry. (2013) 18:666–73. doi: 10.1038/mp.2012.77

73. Lee H, Lee IS, Choue R. Obesity, inflammation and diet. Obes. Res. Clin. Pract. (2018) 14:491–502. doi: 10.1016/j.orscopen.2018.05.012

74. Gray J, Yeo GSH, Cox JJ, Morton J, Adlam AR, Keogh JM, et al. Hyperphagia, severe obesity, impaired cognitive function, and hyperactivity associated with functional loss of one copy of the brain-derived neurotrophic factor (BDNF) gene. Diabetes. (2006) 55:3366–71. doi: 10.2373/diab.06-0550

76. Bariohay B, Lebrun B, Moyse E, Jean A. Brain-derived neurotrophic factor plays a role as an anorexigenic factor in the dorsal vagal complex. J. Physiol. (2006) 573:1189–97. doi: 10.1113/jphysiol.2005.097858

77. Sandrini L, Di Minno A, Amadio P, Ieraci A, Tremoli E, Barbieri SS. The NMDA receptor and schizophrenia: from pathophysiology to treatment. Adv. Pharmacol. (2016) 76:351–82. doi: 10.1006/aps.a.2016.01.006

78. Balu DT. The NMDA receptor and schizophrenia: from pathophysiology to treatment. Adv. Pharmacol. (2016) 76:351–82. doi: 10.1006/aps.a.2016.01.006

79. Erhardt S, Schwieler L, Nilsson L, Linderholm K, Engberg G. The kynurenic acid hypothesis of schizophrenia. Physiol. Behav. (2007) 92:203–9. doi: 10.1016/j.physbeh.2007.05.005

80. Kao AC-C, Safariokova J, Marquardt T, Mullins B, Lennox RR, Burnet PWJ. Pro-cognitive effect of a prebiotic in psychosis: a double blind placebo controlled cross-over study. Schizophr. Res. (2019) 208:460–61. doi: 10.1016/j.schres.2019.03.003

81. Benros ME, Mortensen PB, Nielsen PR. Hospital contacts with infe ction barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J. Nutr. (2009) 139:1619–25. doi: 10.3945/jn.109.104638

82. Takeuchi H, Suzuki T, Remington G, Bies RR, Abe T, Graff-Guerrero A, et al. Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study. Schizophr. Bull. (2013). 39:993–8. doi: 10.1093/schbul/bst090

83. Zseligowski et al. Gut Microbiome and Schizophrenia 2017, vol. 5:14. doi: 10.1016/j.jns.2016.03.033
factor (BDNF) levels: systematic review of literature and meta-analysis. *Int J Mol Sci*. (2018) 19:2281. doi: 10.3390/ijms19082281
78. Cirulli ET, Guo L, Leon Swisher C, Shah N, Huang L, Napier LA, et al. Profound perturbation of the metabolome in obesity is associated with health risk. *Cell Metab*. (2019) 29:488–500. doi: 10.1016/j.cmet.2018.09.022
79. Butte NF, Liu Y, Zakeri IE, Mohney RP, Mehta N, Voruganti VS, et al. Global metabolomic profiling targeting childhood obesity in the Hispanic population. *Am J Clin Nutr*. (2015) 102:256–67. doi: 10.3945/ajcn.115.111872
80. Li Q, Du X, Zhang Y, Yin G, Zhang G, Walss-Bass C, et al. The prevalence, risk factors and clinical correlates of obesity in Chinese patients with schizophrenia. *Psychiatry Res*. (2017) 251:131–6. doi: 10.1016/j.psychres.2016.12.041
81. Kemp DE, Correll CU, Tohen M, Delbello MP, Ganocy SJ, Findling RL, et al. Impact of prebiotics on metabolic and behavioral alterations in a mouse model of metabolic syndrome. *Neurology*. (2006) 67:1208–14. doi: 10.1212/01.wnl.0000238082.13860.50
82. de Cossio LF, Fournier C, Sauvant J, Everard A, Capuron L, Cani PD, et al. Effect of probiotic bacteria isolated from breast milk. *J Biol Chem*. (2008) 283:8579–86. doi: 10.1074/jbc.M108.711104
83. Brown AJ, Goldsworthy SM, Barnes AA, Eilert MM, Tcheang L, Danies D, et al. The orphan G protein-coupled receptors GPR41 and GPR43 are activated by proionate and other short chain carboxylic acids. *J Biol Chem*. (2003) 278:13112–9. doi: 10.1074/jbc.M211609200
84. Ge H, Li X, Weissman J, Wang P, Baribault H, Chen JL, et al. Activation of G protein-coupled receptor 43 in adipocytes leads to inhibition of lipolysis and suppression of plasma free fatty acids. *Endocrinology*. (2008) 149:4519–26. doi: 10.1210/en.2008-0059
85. Lara-Villoslada F, Olivares M, Sierra S, Rodriguez JM, Boza J, Xaus J. Beneficial effects of probiotic bacteria isolated from breast milk. *Br J Nutr*. (2007) 98(Suppl. 1):96. doi: 10.1017/S0007114507832910
86. Dickerson FB, Stallings C, Oringer A, Katsafanas E, Savage CL, Schweinfurth LA, et al. Effect of probiotic supplementation on schizophrenia symptoms and association with gastrointestinal functioning: a randomized, placebo-controlled trial. *Prim Care Companion CNS Disord*. (2014) 16:PCC.13m01579. doi: 10.4088/PCC.13m01579
87. Tomasik J, Yolken R, Bahn S, Dickerson F. Immunomodulatory effects of probiotic supplementation in schizophrenia patients: a randomised placebo-controlled trial. *Biomark Insights*. (2015) 10:47–54. doi: 10.4137/BMI.S22007
88. O’Sullivan E, Barrett E, Grenham S, Fitzgerald F, Stanton C, Ross RP, et al. BDNF expression in the hippocampus of maternally separated rats: does *Bifidobacterium breve* alter BDNF levels? *Benef Microbes*. (2011) 2:199–207. doi: 10.3920/BM2011.0015
89. De Hert M, Hudyana H, Dockx L, Bernagie C, Sweers K, Tack J, et al. Second-generation antipsychotics and constipation: a review of the literature. *Eur Psychiatry*. (2010) 26:34–44. doi: 10.1016/j.eurpsy.2010.03.003
90. Hibbard KR, Props A, Fran DE, Wys J. Fatalities associated with clozapine-related constipation and bowel obstruction: a literature review and two case reports. *Psychosomatics*. (2011) 50:416–9. doi: 10.1176/appi.ps.50.4.416
91. Ghaderi A, Banafshe HR, Mirhosseini N, Moradi M, Karimi MA, Mehrdad F, et al. Clinical and metabolic response to vitamin D plus probiotic in schizophrenia patients. *BMC Psychiatry*. (2019) 19:77. doi: 10.1186/s12888-019-2059-x
92. Okubo R, Koga M, Katsumata N, Odamaki T, Matsuyama S, Oka M, et al. Effect of *Bifidobacterium breve* A-1 on anxiety and depressive symptoms in schizophrenia: a proof-of-concept study. *J Affect Disord*. (2019) 245:377–85. doi: 10.1016/j.jad.2018.11.011
93. Parks OB, Pociask DA, Hodzic Z, Kolls JK, Good M. Interleukin-22 signaling in the regulation of intestinal health and disease. *Front Cell Dev Biol*. (2016) 4:85. doi: 10.3389/fcell.2015.00085
94. Calmon-Hamaty F, Combe B, Hahne M, Morel J. Lymphotoxin and association with gastrointestinal functioning: a randomized, placebo-controlled trial. *BMC Psychiatry*. (2011) 11:54. doi: 10.1186/1471-244X-11-54
95. Park BJ, Szeligowski A. Interleukin-1α and the inflammatory process. *Nat Immunol*. (2017) 18:906–13. doi: 10.1038/ni.3503
96. Paolo NCD, Shayakhmetov DM. Interleukin-1α and the inflammatory process. *Nat Immunol*. (2017) 18:906–13. doi: 10.1038/ni.3503
97. O’Sullivan E, Barrett E, Grenham S, Fitzgerald F, Stanton C, Ross RP, et al. BDNF expression in the hippocampus of maternally separated rats: does *Bifidobacterium breve* alter BDNF levels? *Benef Microbes*. (2011) 2:199–207. doi: 10.3920/BM2011.0015
98. De Hert M, Hudyana H, Dockx L, Bernagie C, Sweers K, Tack J, et al. Second-generation antipsychotics and constipation: a review of the literature. *Eur Psychiatry*. (2010) 26:34–44. doi: 10.1016/j.eurpsy.2010.03.003
99. Hibbard KR, Props A, Fran DE, Wys J. Fatalities associated with clozapine-related constipation and bowel obstruction: a literature review and two case reports. *Psychosomatics*. (2011) 50:416–9. doi: 10.1176/appi.ps.50.4.416
100. Ghaderi A, Banafshe HR, Mirhosseini N, Moradi M, Karimi MA, Mehrdad F, et al. Clinical and metabolic response to vitamin D plus probiotic in schizophrenia patients. *BMC Psychiatry*. (2019) 19:77. doi: 10.1186/s12888-019-2059-x
101. Okubo R, Koga M, Katsumata N, Odamaki T, Matsuyama S, Oka M, et al. Effect of *Bifidobacterium breve* A-1 on anxiety and depressive symptoms in schizophrenia: a proof-of-concept study. *J Affect Disord*. (2019) 245:377–85. doi: 10.1016/j.jad.2018.11.011
102. Parks OB, Pociask DA, Hodzic Z, Kolls JK, Good M. Interleukin-22 signaling in the regulation of intestinal health and disease. *Front Cell Dev Biol*. (2016) 4:85. doi: 10.3389/fcell.2015.00085
103. Calmon-Hamaty F, Combe B, Hahne M, Morel J. Lymphotoxin and association with gastrointestinal functioning: a randomized, placebo-controlled trial. *BMC Psychiatry*. (2011) 11:54. doi: 10.1186/1471-244X-11-54
104. Paolo NCD, Shayakhmetov DM. Interleukin-1α and the inflammatory process. *Nat Immunol*. (2017) 18:906–13. doi: 10.1038/ni.3503
Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Szeligowski, Yun, Lennox and Burnet. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.